{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:23:12Z","timestamp":1779200592714,"version":"3.51.4"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00386","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T01:04:57Z","timestamp":1557795897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Epstein-Barr Virus-Positive Natural Killer\/T-Cell Lymphoma"],"prefix":"10.3389","volume":"9","author":[{"given":"Qingqing","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1200\/jco.1999.17.4.1322","article-title":"Lethal midline granuloma revisited: nasal T\/Natural-killer cell lymphoma","volume":"17","author":"Chim","year":"1999","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10147-009-0882-7","article-title":"Nasal natural killer (NK)\/T-cell lymphoma: clinical, histological, virological, and genetic features","volume":"14","author":"Harabuchi","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0140-6736(90)90002-M","article-title":"Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma","volume":"335","author":"Harabuchi","year":"1990","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V87.2.839.bloodjournal872839","article-title":"Clarification of CD3 immunoreactivity in nasal T\/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+","volume":"87","author":"Chan","year":"1996","journal-title":"Blood"},{"key":"B5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017"},{"key":"B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/nejm198803243181203","article-title":"T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections","volume":"318","author":"Jones","year":"1988","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0324-5","article-title":"Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma","author":"Peng","year":"2018","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1038\/emm.2014.105","article-title":"Epstein-Barr virus-positive T\/NK-cell lymphoproliferative disorders","volume":"47","author":"Cai","year":"2015","journal-title":"Exp Mol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-319-22834-1_12","article-title":"Immune evasion by Epstein-Barr virus","volume":"391","author":"Ressing","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/nejm200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5604\/17322693.1050999","article-title":"Epstein-Barr virus-associated lymphoproliferative disorders","volume":"67","author":"Grywalska","year":"2013","journal-title":"Postepy Hig Med Dosw"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3892\/or.2015.3847","article-title":"LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-kappaB and PI3K\/Akt signaling pathways in nasal NK\/T-cell lymphoma","volume":"33","author":"Sun","year":"2015","journal-title":"Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.3892\/or.2015.4305","article-title":"LMP1 promotes nasal NK\/T-cell lymphoma cell function by eIF4E via NF-kappaB pathway","volume":"34","author":"Sun","year":"2015","journal-title":"Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40880-018-0334-8","article-title":"IL-2Ralpha up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer\/T-cell lymphoma","volume":"38","author":"Wang","year":"2018","journal-title":"Cancer Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s1470-2045(16)30148-6","article-title":"Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study","volume":"17","author":"Li","year":"2016","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1073\/pnas.171360711510.15252\/emmm.201708292","article-title":"Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility","volume":"10","author":"Cantor","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.critrevonc.2016.10.014","article-title":"Primary immunodeficiencies associated with EBV-Induced lymphoproliferative disorders","volume":"108","author":"Shabani","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.4459","article-title":"The Epstein-Barr virus and the pathogenesis of lymphoma","volume":"235","author":"Vockerodt","year":"2015","journal-title":"J Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ijc.25969","article-title":"Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer\/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15","volume":"130","author":"Ishii","year":"2012","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13045-018-0559-710.1038\/nm.4456","article-title":"Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK\/T cell lymphoma","volume":"24","author":"Wen","year":"2018","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","article-title":"Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses","volume":"118","author":"Karube","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.ajpath.2014.07.011","article-title":"HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer\/T-cell lymphoma pathophysiology","volume":"184","author":"Sako","year":"2014","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2009.3","article-title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies","volume":"23","author":"Iqbal","year":"2009","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cyto.1069","article-title":"Comparative genomic hybridization study of nasal-type NK\/T-cell lymphoma","volume":"46","author":"Ko","year":"2001","journal-title":"Cytometry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/onc.2013.107","article-title":"DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2\/Slug\/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer","volume":"33","author":"Wu","year":"2013","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1158\/1078-0432.ccr-10-2316","article-title":"Reduced p21(WAF1\/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/(sici)1521-4141(199803)28:03<805::aid-immu805>3.0.co;2-g","article-title":"Jak-STAT pathway is involved in the induction of TNF-beta gene during stimulation by IL-2","volume":"28","author":"Lu","year":"1998","journal-title":"Eur J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.cd-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","article-title":"Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma","volume":"125","author":"Chen","year":"2015","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.2823","article-title":"Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK\/T cell lymphoma revealed by gene expression profiling","volume":"223","author":"Ng","year":"2011","journal-title":"J Pathol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vire","year":"2006","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1038\/sj.onc.1207755","article-title":"Oncogenic potential of the RUNX gene family: 'overview'","volume":"23","author":"Ito","year":"2004","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0065-230x(07)99002-8","article-title":"RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes","volume":"99","author":"Ito","year":"2008","journal-title":"Adv Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/leu.2017.40","article-title":"RUNX3 is oncogenic in natural killer\/T-cell lymphoma and is transcriptionally regulated by MYC","volume":"31","author":"Selvarajan","year":"2017","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.ccr-14-1216","article-title":"Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma","volume":"21","author":"Kucuk","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/gcc.22348","article-title":"Frequent BCOR aberrations in extranodal NK\/T-Cell lymphoma, nasal type","volume":"55","author":"Dobashi","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1182\/blood-2011-07-364224","article-title":"Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer\/T-cell lymphoma","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.beha.2013.04.006","article-title":"Molecular underpinning of extranodal NK\/T-cell lymphoma","volume":"26","author":"Huang","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/hon.2362","article-title":"Hypermethylation of PRDM1\/Blimp-1 promoter in extranodal NK\/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation","volume":"35","author":"Zhang","year":"2017","journal-title":"Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajpath.2017.01.004","article-title":"Novel JAK3-activating mutations in extranodal NK\/T-cell lymphoma, nasal type","volume":"187","author":"Sim","year":"2017","journal-title":"Am J Pathol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41375-017-0004-x","article-title":"Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer\/T-cell lymphoma","volume":"32","author":"Nairismagi","year":"2018","journal-title":"Leukemia"},{"key":"B51","unstructured":"A phase II study of bortezomib-GIFOX (Gemcitabine, Ifosfamide, Oxaliplatin) in patients with newly diagnosed natural-killer\/T-cell lymphoma5353 TangT TayK TaoM QuekRHH FaridM LimST Blood1282016"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.3324\/haematol.2014.116087","article-title":"Serum survivin and vascular endothelial growth factor in extranodal NK\/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator","volume":"100","author":"Kim","year":"2015","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1158\/1078-0432.ccr-11-0494","article-title":"MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK\/T cell lymphoma","volume":"17","author":"Paik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ajh.23570","article-title":"Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK\/T-cell lymphoma","volume":"89","author":"Komabayashi","year":"2014","journal-title":"Am J Hematol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-016-0368-9","article-title":"Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK\/T cell lymphoma","volume":"10","author":"Huang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/s2352-3026(15)00002-2","article-title":"Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis","volume":"2","author":"Kim","year":"2015","journal-title":"Lancet Haematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2014","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/jco.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejm199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International","year":"1993","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/leu.2015.44","article-title":"Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/jco.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijrobp.2016.09.013","article-title":"Patterns of primary tumor invasion and regional lymph node spread based on magnetic resonance imaging in early-stage nasal NK\/T-cell lymphoma: implications for clinical target volume definition and prognostic significance","volume":"97","author":"Wu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B67","doi-asserted-by":"publisher","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK\/T cell lymphoma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/bjc.2012.566","article-title":"Fasting blood glucose is a novel prognostic indicator for extranodal natural killer\/T-cell lymphoma, nasal type","volume":"108","author":"Cai","year":"2013","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00277-014-2089-x","article-title":"New prognostic model for extranodal Natural Killer\/T cell lymphoma, nasal type","volume":"93","author":"Cai","year":"2014","journal-title":"Ann Hematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40880-017-0229-0","article-title":"Prognostic role of ABO blood type in patients with extranodal Natural Killer\/T cell lymphoma, nasal type: a triple-center study","volume":"36","author":"Li","year":"2017","journal-title":"Chin J Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40880-017-0212-9","article-title":"CD30 expression in extranodal natural killer\/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China","volume":"36","author":"Feng","year":"2017","journal-title":"Chin J Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"11480","DOI":"10.18632\/oncotarget.14006","article-title":"Radiotherapy improves survival in early stage extranodal Natural Killer\/T cell lymphoma patients receiving asparaginase-based chemotherapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","article-title":"Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: a multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"129","author":"Deng","year":"2018","journal-title":"Radiother Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","article-title":"Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer\/T-cell lymphoma","volume":"3","author":"Yang","year":"2017","journal-title":"JAMA Oncol"},{"key":"B75","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"256","DOI":"10.18632\/oncotarget.1810710.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/cncr.26629","article-title":"Phase 2 trial of \u201csandwich\u201d L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma","volume":"118","author":"Jiang","year":"2012","journal-title":"Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3892\/ol.2015.3327","article-title":"First-line combination of GELOX followed by radiation therapy for patients with stage IE\/IIE ENKTL: an updated analysis with long-term follow-up","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00277-017-3046-2","article-title":"Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I\/II extranodal Natural Killer\/T cell lymphoma, nasal type","volume":"96","author":"Huang","year":"2017","journal-title":"Ann Hematol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1200\/jco.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1200\/jco.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ejca.2015.07.009","article-title":"Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)\/T-cell lymphoma, nasal type","volume":"51","author":"Michot","year":"2015","journal-title":"Eur J Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hon.2273","article-title":"Novel treatment for early-stage nasal natural killer\/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy","volume":"35","author":"Takahara","year":"2017","journal-title":"Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"85584","DOI":"10.18632\/oncotarget.11319","article-title":"Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I\/II extranodal NK\/T-cell lymphoma, nasal type (CISL-1008)","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"50155","DOI":"10.18632\/oncotarget.16334","article-title":"A phase II prospective study of the \u201cSandwich\u201d protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I\/II stage, nasal type, extranodal natural killer\/T-cell lymphoma","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1038\/bcj.2014.88","article-title":"Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell lymphoma","volume":"4","author":"Ke","year":"2014","journal-title":"Blood Cancer J"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/jco.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12185-015-1809-x","article-title":"High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed\/refractory extranodal Natural Killer\/T cell lymphoma: a retrospective study","volume":"102","author":"Ding","year":"2015","journal-title":"Int J Hematol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"29092","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e2787","DOI":"10.1097\/md.0000000000002787","article-title":"GDP (Gemcitabine, Dexamethasone, and Cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed\/refractory extranodal natural killer\/T-cell lymphoma, nasal type","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mdn542","article-title":"L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature","volume":"20","author":"Jaccard","year":"2009","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1158\/1078-0432.ccr-16-0153","article-title":"DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal Natural Killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B100","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12185-017-2324-z","article-title":"Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma, nasal type: a retrospective controlled study in a single center","volume":"107","author":"Wang","year":"2018","journal-title":"Int J Hematol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone marrow Transplant"},{"key":"B102","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2017","journal-title":"Br J Haematol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/jco.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term Outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/jco.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T02:11:27Z","timestamp":1574647887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":112,"alternative-id":["10.3389\/fonc.2019.00386"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00386","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"article-number":"386"}}